Top Markets
Coin of the day
AstraZeneca PLC AstraZeneca PLC

AstraZeneca PLC

AZN
Pozycja w akcjach #5596
AstraZeneca PLC operates as a biopharmaceutical company, specializing in the... AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology conditions are targeted by products like Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Additionally, rare diseases are treated with Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. The company's product offerings also extend to Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; Nexium and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for COVID-19. AstraZeneca serves primary and specialty care physicians globally, leveraging a network of distributors and local representative offices across the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. Strategic collaboration forms a vital component of its operations. Partnerships include an agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG for the development and commercialization of NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH for the joint discovery of novel small molecules targeting hematological cancers; and Sierra Oncology, Inc. for the development and commercialization of AZD5153. Initially incorporated in 1992 as Zeneca Group PLC, the company adopted its current name, AstraZeneca PLC, in April 1999. It is headquartered in Cambridge, United Kingdom.
Cena akcji
$165.87
Kapitalizacja rynkowa
$2.57B
Zmiana (1 dzień)
-0.36%
Zmiana (1 rok)
3.47%
Kraj
GB
Handel AstraZeneca PLC (AZN)

Kategoria

Historia ceny akcji dla AstraZeneca PLC (AZN)
Najwyższa cena zamknięcia: $162.69 dnia 2026-08-01

Najniższa cena zamknięcia: $8.25 dnia 1993-05-01
Historia cen akcji firmy AstraZeneca PLC od 1993 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2026 (TTM) -0.49%
2025 37.48%
2024 1.62%
2023 -4.75%
2022 22.39%
2021 8.59%
2020 5.53%
2019 28.71%
2018 16.37%
2017 22.71%
2016 -20.37%
2015 -7.09%
2014 24.32%
2013 20.93%
2012 4.68%
2011 -2.97%
2010 2.21%
2009 17.38%
2008 -13.55%
2007 -18.46%
2006 15.66%
2005 25.75%
2004 -17.16%
2003 27.24%
2002 -18.63%
2001 -9.08%
2000 16.92%
1999 23.36%
1998 26.90%
1997 24.21%
1996 28.50%
1995 46.78%
1994 7.72%
1993 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$1.19K 62.31%
US
$270.41 52.96%
US
$263.20 26.50%
US
$487.71 41.89%
CH
$153.19 82.22%
US